## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 85 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (85).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.92)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook**
- Source: AD HOC NEWS | 20251230T110857 | Bullish | Relevance: 100%
- Exact Sciences Corp. is transforming cancer screening into a software-driven diagnostics platform, making early detection more routine. The company is known for its Cologuard at-home colon cancer screening test and has expanded into multi-cancer early detection and precision oncology. Their strategy focuses on noninvasive screening, precision oncology tools like Oncotype DX, and developing multi-cancer early detection (MCED) via a data-driven approach, positioning them as a critical infrastructure in cancer care.

**2. Exact Sciences accelerates executive bonuses and equity awards ahead of merger**
- Source: Investing.com | 20251229T140913 | Neutral | Relevance: 100%
- Exact Sciences Corp. announced that its board has approved accelerated vesting and payment of annual bonuses and equity awards for executive officers. This decision is related to the company's pending merger with Abbott Laboratories and aims to address potential tax implications under Sections 280G and 4999 of the Internal Revenue Code. The move also outlines specific accelerated payments for key executives and details regarding annual bonuses, RSU, and PSU awards, along with clawback provisions.

**3. Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS**
- Source: MarketBeat | 20251228T000948 | Somewhat-Bearish | Relevance: 100%
- Harbor Capital Advisors Inc. significantly reduced its stake in Exact Sciences Corporation by selling 29,990 shares, decreasing its holdings by 61.6% to 18,705 shares. This comes amidst mixed analyst ratings, with a current consensus of "Hold" and a price target of $85, despite Exact Sciences beating Q3 earnings and revenue estimates. Insider selling has also been reported, with executives and directors offloading shares.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Overbought RSI (85) with bearish MACD signals exhaustion.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 91.1x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $102.66 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 91.1 |
| Current P/E | 301.4 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -1.3% to -0.2% (+1.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.7%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.26), momentum weakening. RSI overbought at 85, risk of mean reversion. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.23% (CS: 52) | Neutral |
| RSI_14 | 85.3 | Overbought |
| MACD Histogram | -1.26 | Bearish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.192x | Above |
| vs SMA200 | 1.715x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.90
- **Stop Loss:** $99.92 (1.9% risk)
- **Target:** $103.88 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 666
- **Position Value:** $67,865.40
- **Portfolio %:** 67.87%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*